Strategic Acquisition Leverage the fact that IM HealthScience was acquired by Nestlé Health Science in 2020. This indicates a successful exit and integration into a larger corporate ecosystem, suggesting potential joint opportunities, distribution leverage, or co-branded medical foods channels with Nestlé’s global reach.

Medical Foods Focus Target healthcare providers and specialty clinics that treat IBS, Functional Dyspepsia, Diverticulosis, Ulcerative Colitis, and Crohn’s Disease. IMH’s emphasis on medical foods positioned for patients requiring dietary interventions presents a niche in GI care that can be expanded through clinician education and pilot programs.

Small but Specialized With a lean team and annual revenue under a million, there is appetite for partnerships that accelerate market access, including manufacturing scale-ups, co-development of new formulations, and channel partnerships with gastroenterology practices and pharmacies.

Evidence and Education Highlight IMH’s commitment to strong science, well-studied ingredients, and smart delivery as a differentiator to healthcare buyers. Build opportunities around clinical data packages, continuing medical education (CME) collaborations, and post-market studies to support adoption.

Brand and Portfolio Leverage Explore cross-sell potential across existing IMH brands such as IBgard, FDgard, Fiber Choice, and REMfresh through distributor networks or contract manufacturing partnerships to expand into new geographies or healthcare systems.